BNP Paribas Financial Markets Takes Position in Can-Fite BioPharma Ltd. (NYSE:CANF)

BNP Paribas Financial Markets purchased a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Rhumbline Advisers boosted its stake in Can-Fite BioPharma by 58.6% during the fourth quarter. Rhumbline Advisers now owns 26,880 shares of the company’s stock worth $44,000 after buying an additional 9,935 shares during the period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Stock Up 0.5%

NYSE CANF opened at $1.10 on Wednesday. The company has a fifty day moving average of $1.20 and a two-hundred day moving average of $1.49. The firm has a market capitalization of $3.89 million, a price-to-earnings ratio of -0.61 and a beta of 1.18. Can-Fite BioPharma Ltd. has a 52 week low of $0.98 and a 52 week high of $4.69.

Analyst Ratings Changes

Several research firms have commented on CANF. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, April 15th. Wall Street Zen began coverage on shares of Can-Fite BioPharma in a research note on Thursday, April 24th. They set a “sell” rating for the company.

Can-Fite BioPharma Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.